Staunch biotech competition spurs new secretive tactics, shifts investor approach
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to…
10 Sep 2026
Podcast: key readouts from ESC and ERS
It's conference season again. In this episode, the healthcare team rounds up the latest readouts and emerging themes from two recent events: the European Society of Cardiology (ESC) Congress and…
08 Sep 2026
Osaka has the science. Now it needs the business
Osaka has the science. Now it needs to build the companies, capital and global reach to turn that science into an industry. Kansai - the Japanese region encompassing Osaka, Kyoto…
02 Sep 2026
Peptide innovator says the drug class is due for a rethink
The FDA’s acceptance of several untested peptides for human use has left one drug innovator calling for a greater clarity of understanding around a drug class that is widely known…
28 Aug 2026
MSD’s Lipfendra takes on injectable rivals for cholesterol-lowering market supremacy
Filling a Keytruda-sized sales void was always going to be challenging, but Merck & Co (MSD) may have crafted a medicine that can go some way in maintaining healthy revenue…
27 Aug 2026
MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones
The US policy of Most Favoured Nation (MFN) pricing has raised uncertainty in European markets reluctant to raise drug prices and driven a debate among Europe’s smaller countries around whether…
24 Aug 2026
A strategic shift for gene therapies: manufacturing and market size take centre stage
Despite fostering cutting-edge science, gene therapy biotechs have sometimes failed to reach commercial heights due to inherent scalability hurdles. Consequently, the sector has faced dwindling investor sentiment in recent years.…